884 participants
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-04
- Start Date:
- 2022-12-07
- Completion:
- 2027-07-31
Conditions
- High Grade Epithelial Ovarian Cancer
- High Grade Serous Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
- Mesothelioma
- Breast Adenocarcinoma
- Triple Negative Breast Cancer
- Hormone Receptor-positive/Her2 Negative Breast Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Platinum Sensitive Ovarian Cancer (PSOC)
- Primary Refractory Ovarian Cancer
- Uterine Cancer
Interventions
- DRUG
No Results Yet